^
Association details:
| Biomarker: | STMN2 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel
Excerpt:
...analysis of The Cancer Genome Atlas patient data showed that high STMN2 levels correlate with complete regression of tumors in response to taxane treatment.
DOI:
10.1073/pnas.2024055118
